CIRCOVAC® is the 1st PCV2 vaccine providing global herd protection

Porcine circovirus Type 2 infection has been reported from nearly every country with a significant commercial swine production industry. It is strongly associated with the occurrence of PMWS and also appears to have an association with porcine dermatitis and nephropathy syndrome (PDNS), porcine respiratory disease complex (PRDC), and occasionally reproductive failure.

CIRCOVAC® is the inactivated PCV2 vaccine, formulated based on the whole PCV2 virus and a potent adjuvant inducing a strong humoral and cellular immune response. Thanks to a registration for piglets, gilts and sows, Circovac® provides the whole life piglet protection. The efficacy has been demonstrated against all relevant PCV2 genotypes. The active immunisation allows reducing the faecal and nasal excretion of PCV2 and virus load in blood and is an aid to reduce PCV2 linked clinical signs.

From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the CEVA Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.

Back to top